<DOC>
	<DOCNO>NCT01955733</DOCNO>
	<brief_summary>The primary objective trial evaluate long-term safety BI 695500 adult patient moderately severely active rheumatoid arthritis ( RA ) successfully complete treatment Trial 1301.1 .</brief_summary>
	<brief_title>Safety Efficacy BI 695500 Patients With Moderately Severely Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion criterion : 1 . Must give write informed consent willing follow CTP . 2 . Male female patient , moderately severely active RA previously participate doubleblind randomized clinical Trial 1301.1 . 3 . Current treatment RA outpatient basis : 1 . Patients must continue receive tolerate oral parenteral methotrexate ( MTX ) therapy dose 1525 mg per week ( dose may low 10 mg per week patient unable tolerate high dose ) . 2 . Patients must willing receive oral folic acid ( least 5 mg/week per local practice ) folinic acid ( least 1 mg per week per local practice ) equivalent entire trial . 3 . If receiving current treatment oral corticosteroid ( intraarticular parenteral ) , dose must exceed 10 mg/day prednisolone equivalent . During 4 week prior Baseline ( Day 1 ) dose must remain stable . 4 . Intraarticular parenteral corticosteroid permit throughout trial , exception IV administration 100 mg methylprednisolone 30 60 minute prior infusion part trial procedure . 5 . Any concomitant nonsteroidal antiinflammatory drug ( NSAIDs ) must stable throughout trial . 6 . Patients may take oral hydroxychloroquine provide dose great 400 mg/day , chloroquine provide dose great 250 mg/day . These dos must stable minimum 12 week prior Day 1 . The hydroxychloroquine chloroquine treatment need continue stable dose formulation end trial . 4 . For participant reproductive potential ( male female ) , use medically acceptable method contraception trial , i.e. , combination 2 form effective contraception ( defined hormonal contraception , intrauterine device , condom spermicide , etc. ) . Females childbearing potential must also agree use acceptable method contraception ( see ) 12 month follow completion discontinuation trial medication . Exclusion criterion : 1 . Patients receive current treatment corticosteroid must receive dose exceed 10 mg/day prednisone equivalent . 2 . Serious underlie medical condition , , per investigator¿s discretion , could impair ability patient participate trial ( include limit ongoing severe infection , severe immunosuppression , severe heart failure , uncontrolled hypertension , uncontrolled diabetes mellitus , gastric ulcer , active autoimmune disease ) . 3 . Pregnancy breast feeding . For woman childbearing potential , positive serum pregnancy test Screening Visit . 4 . Patients significant cardiac disease , include limited congestive heart failure Class III IV New York Heart Association ( NYHA ) classification ; uncontrolled angina arrhythmia ; uncontrolled severe cardiovascular cerebrovascular disease ; uncontrolled hypertension . 5 . Treatment IV intramuscular corticosteroid . The exception administration 100 mg IV methylprednisolone 30 60 minute infusion part trial procedure . 6 . Any condition treatment ( include biologic therapy ) , opinion investigator , may place patient unacceptable risk trial . 7 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 time upper limit normal ( ULN ) . 8 . Hemoglobin &lt; 8.0 g/dL . 9 . Levels IgG &lt; 5.0 g/L . 10 . Absolute neutrophil count &lt; 1500/µL . 11 . Platelet count &lt; 75000/µL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>82 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>